New Joint FDA/NCI Cancer Program

Publication
Article
OncologyONCOLOGY Vol 15 No 9
Volume 15
Issue 9

The Food and Drug Administration (FDA) and the National Cancer Institute (NCI) inaugurated a new program in July that

The Food and Drug Administration (FDA) and the National Cancer Institute (NCI) inaugurated a new program in July that willintegrate the study of all proteins in living cells (or proteomics) with patientcare. 

"This new approach to treatment holds the potential to revolutionizecancer detection and care," said Health and Human Services Secretary TommyG. Thompson. The agency collaboration is being led by Emanuel Petricoin, PhD, ofthe FDA’s Center for Biologics Evaluation and Research, and Lance Liotta, MD,PhD, of NCI’s Center for Cancer Research. 

The Clinical Proteomics Program willbe funded for 3 years at $1.1 million per year. Drs. Petricoin and Liotta haveidentified more than 130 proteins in cancers of the breast, ovary, prostate, andesophagus that change in amount as the cells in these tissues grow abnormally,which may provide new means of diagnosing and treating cancers earlier. The NCIhas recently begun clinical trials using proteomics to help make decisions aboutthe course of a patient’s experimental treatment.

Recent Videos
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.
Patients with unresectable or metastatic esophageal squamous cell carcinoma and higher PD-L1 expression may benefit from treatment with tislelizumab, according to Syma Iqbal, MD.
Related Content